By Colin Kellaher
Mineralys Therapeutics on Monday reported positive topline results from a pair of pivotal studies of its lorundrostat drug candidate for the treatment of uncontrolled or resistant hypertension.
Mineralys said its Phase 3 Launch-HTN and Phase 2 Advance-HTN studies achieved statistical significance and were clinically meaningful in their pre-specified primary efficacy endpoints while showing a favorable safety and tolerability profile.
The Radnor, Pa., clinical-stage biopharmaceutical company said it believes the clinical profile observed for lorundrostat supports the potential regulatory approval of the drug, which it said has the potential to be a transformative new therapy for the roughly 15 million to 20 million people in the U.S. living with uncontrolled hypertension.
Trading in shares of Mineralys, which closed Friday at $10.52, was halted premarket on Monday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 10, 2025 07:19 ET (11:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。